 |
 |
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Jun 07, 2023 |
Title |
Effect |
Organisms |
Homo sapiens; Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
37270599 |
|
Submission date |
Jan 19, 2023 |
Last update date |
Jun 08, 2023 |
Contact name |
Ann Richmond |
E-mail(s) |
ann.richmond@Vanderbilt.Edu
|
Organization name |
Vanderbilt University School of Medicine
|
Department |
Department of Pharmacology and Dermatology
|
Street address |
2220 Pierce Avenue
|
City |
Nashviile |
State/province |
TN |
ZIP/Postal code |
37232 |
Country |
USA |
|
|
Platforms (2) |
GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
Samples (47)
|
GSM6944448 |
NHEM, CXCL1, rep2 |
GSM6944449 |
NHEM, CXCL1, SX682, rep1 |
GSM6944450 |
NHEM, CXCL1, SX682, rep2 |
GSM6944451 |
control, rep1 |
GSM6944452 |
control, rep2 |
GSM6944453 |
control, rep3 |
GSM6944454 |
control, rep4 |
GSM6944455 |
control, rep5 |
GSM6944456 |
control, rep6 |
GSM6944457 |
SX-682, rep1 |
GSM6944458 |
SX-682, rep2 |
GSM6944459 |
SX-682, rep3 |
GSM6944460 |
SX-682, rep4 |
GSM6944461 |
CXCR2 Wild Type, rep1 |
GSM6944462 |
CXCR2 Wild Type, rep2 |
GSM6944463 |
CXCR2 Wild Type, rep3 |
GSM6944464 |
CXCR2 Wild Type, rep4 |
GSM6944465 |
CXCR2 Wild Type, rep5 |
GSM6944466 |
CXCR2 Wild Type, rep6 |
GSM6944467 |
CXCR2 Wild Type, rep7 |
GSM6944468 |
CXCR2 Knockout, rep1 |
GSM6944469 |
CXCR2 Knockout, rep2 |
GSM6944470 |
CXCR2 Knockout, rep3 |
GSM6944471 |
CXCR2 Knockout, rep4 |
GSM6944472 |
CXCR2 Knockout, rep5 |
GSM6944473 |
CXCR2 Knockout, rep6 |
GSM6944474 |
CXCR2 Knockout, rep7 |
GSM6944475 |
CXCR2 Knockout, rep8 |
GSM6944476 |
MelanA, no treatment, rep1 |
GSM6944477 |
MelanA, no treatment, rep2 |
GSM6944478 |
MelanA, SX-682 treatment, rep1 |
GSM6944479 |
MelanA, SX-682 treatment, rep2 |
GSM6944480 |
B16F0, no treatment, rep1 |
GSM6944481 |
B16F0, no treatment, rep2 |
GSM6944482 |
B16F0, SX-682 treatment, rep1 |
GSM6944483 |
B16F0, SX-682 treatment, rep2 |
GSM6944484 |
B16F10, no treatment, rep1 |
GSM6944485 |
B16F10, no treatment, rep2 |
GSM6944486 |
B16F10, SX-682 treatment, rep1 |
GSM6944487 |
B16F10, SX-682 treatment, rep2 |
GSM6944488 |
B16F0, DMSO, IgG |
GSM6944489 |
B16F0, SX682, igG |
GSM6944490 |
B16F0, DMSO, TFCP2L1 |
GSM6944491 |
B16F02L1, SX682, TFCP2L1 |
|
This SuperSeries is composed of the following SubSeries:
|
GSE223285 |
Effect of CXCL1 and CXCL1 with SX-682 on gene expression for human epidermal melanocytes (NHEM) cells. |
GSE223286 |
Effect of SX-682 on gene expression for BrafV600E/PTEN-/- mice. |
GSE223287 |
Effect of CXCR2 knockout on gene expression of BRAFV600E/PTEN-/- mice |
GSE223288 |
Effect of SX-682 treatment on gene expressions of three murine cell lines. |
GSE223289 |
ChIPseq analysis of changes in binding of TFCP2L1 antibody in B16F0 cells in response to SX-682 treatment. |
|
Relations |
BioProject |
PRJNA925522 |
|
|
|
|
 |